Drug Trial Radar · NCT04475224
Phase 3 Study of KP-100IT in Subjects With Acute Spinal Cord Injury
Last checked: Nov 19, 2026Latest source record: Aug 26, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
25
Planned (sponsor's estimate)
Start
Jul 13, 2020
Primary completion
Dec 31, 2022
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- Kringle Pharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 17, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 89 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is non-randomized, multicenter, confirmatory study by intrathecal administration of KP-100IT, code of HGF (Hepatocyte Growth Factor ) formulation for intrathecal injection, in subjects with acute spinal cord injury.
Conditions
- Acute Spinal Cord Injury
Interventions
KP-100ITDrug
Intrathecal injection of 0.6 mg HGF starting at 72 hours since the injury and repeating weekly 5 times
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of subjects with an improvement of at least two AIS (American Spinal Injury Association) grade, A to C/D, at 24 weeks after administrationTime frame: 24 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Spinal Injuries Center
Iizuka, Fukuoka, Japan · Recruiting
Hokkaido Spinal Cord Injury Center
Bibai, Hokkaido, Japan · Recruiting
Japanese Red Cross Kobe Hospital
Kobe, Hyōgo, Japan · Recruiting
Aijinkai Rehabilitation Hospital
Takatsuki, Osaka, Japan · Recruiting
Murayama Medical Center
Musashimurayama, Tokyo, Japan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.